MaltSci 麦伴科研

Appearance

Popular Reports / psychiatry

This report is written by MaltSci based on the latest literature and research findings

What is the role of genetics in psychiatric disorders? ​

Abstract ​

The role of genetics in psychiatric disorders has garnered increasing attention due to advancements in genomic technologies that illuminate the intricate relationships between genetic variations and mental health conditions. Psychiatric disorders, characterized by multifactorial etiologies, involve both genetic and environmental factors that contribute to their onset and progression. Understanding these relationships is essential for developing effective prevention and treatment strategies, as psychiatric disorders account for a significant global health burden. This report reviews the genetic foundations of major psychiatric disorders, including schizophrenia, bipolar disorder, major depressive disorder, and autism spectrum disorders, highlighting the heritable components evidenced by family, twin, and adoption studies. Recent research methodologies, particularly genome-wide association studies (GWAS) and next-generation sequencing (NGS), have identified numerous genetic variants linked to increased risk of these conditions, emphasizing the polygenic nature of psychiatric disorders. Furthermore, the interplay between genetic predispositions and environmental factors is explored, particularly through epigenetic mechanisms that mediate the effects of environmental stressors on mental health. The implications of these findings for treatment and personalized medicine are discussed, underscoring the potential for pharmacogenomics to enhance clinical care. Despite the progress made, limitations in current genetic research are acknowledged, particularly the challenges associated with gene-environment interactions. This review aims to inform clinicians, researchers, and policymakers about the critical role of genetics in psychiatric disorders, guiding future research directions and clinical applications.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 Genetic Foundations of Psychiatric Disorders
    • 2.1 Overview of Genetic Concepts
    • 2.2 Heritability and Family Studies
  • 3 Major Psychiatric Disorders and Genetic Links
    • 3.1 Schizophrenia
    • 3.2 Bipolar Disorder
    • 3.3 Major Depressive Disorder
    • 3.4 Autism Spectrum Disorders
  • 4 Advances in Genetic Research Methodologies
    • 4.1 Genome-Wide Association Studies (GWAS)
    • 4.2 Next-Generation Sequencing (NGS)
    • 4.3 Epigenetics and Gene Expression
  • 5 Gene-Environment Interactions
    • 5.1 The Role of Environmental Factors
    • 5.2 Epigenetic Modifications
  • 6 Implications for Treatment and Personalized Medicine
    • 6.1 Pharmacogenomics
    • 6.2 Future Directions in Treatment Approaches
  • 7 Summary

1 Introduction ​

The role of genetics in psychiatric disorders has become an increasingly prominent area of research, particularly as advancements in genomic technologies have illuminated the intricate relationships between genetic variations and mental health conditions. Psychiatric disorders, characterized by complex multifactorial etiologies, involve both genetic and environmental factors that contribute to their onset and progression. Understanding these relationships is essential for developing more effective prevention and treatment strategies, as psychiatric disorders represent a significant burden on global health systems, accounting for a substantial proportion of disability-adjusted life years lost worldwide [1].

The significance of exploring genetic contributions to psychiatric disorders lies not only in elucidating the underlying biological mechanisms but also in enhancing clinical practices through personalized medicine. Genetic predispositions can influence an individual's vulnerability to various psychiatric conditions, including schizophrenia, bipolar disorder, major depressive disorder, and autism spectrum disorders [2][3]. By identifying specific genetic markers and understanding their interactions with environmental factors, researchers can pave the way for tailored therapeutic interventions that account for individual genetic profiles, potentially improving treatment outcomes [4].

Current research has established a substantial heritable component in many psychiatric disorders, supported by traditional family, twin, and adoption studies [5]. However, the complexity of these disorders is underscored by the observation of discordance among identical twins, suggesting that environmental factors also play a crucial role [6]. Recent advances in genetic methodologies, including genome-wide association studies (GWAS) and next-generation sequencing (NGS), have provided insights into the genetic architecture of these disorders, revealing both common and rare genetic variants associated with increased risk [7][8].

This report is organized into several sections that will comprehensively address the multifaceted role of genetics in psychiatric disorders. The first section will provide an overview of genetic concepts, including heritability and findings from family studies, establishing a foundational understanding of the genetic underpinnings of these conditions. Following this, we will explore the major psychiatric disorders and their genetic links, focusing on schizophrenia, bipolar disorder, major depressive disorder, and autism spectrum disorders.

Subsequently, we will discuss recent advancements in genetic research methodologies, emphasizing the significance of GWAS, NGS, and the emerging field of epigenetics in understanding psychiatric disorders. The interplay between genetic and environmental factors will be examined in detail, particularly how epigenetic modifications can mediate the effects of environmental stressors on mental health [8][9]. The implications of these findings for treatment and personalized medicine will also be addressed, highlighting the potential of pharmacogenomics in enhancing clinical care.

Finally, the report will summarize the key findings and discuss the limitations of current genetic research, particularly the challenges associated with gene-environment interactions and the need for further exploration in this domain. By synthesizing these insights, this review aims to inform clinicians, researchers, and policymakers about the critical role genetics plays in psychiatric disorders, ultimately guiding future research directions and clinical applications.

2 Genetic Foundations of Psychiatric Disorders ​

2.1 Overview of Genetic Concepts ​

Genetic factors play a significant role in the etiology of various psychiatric disorders, as evidenced by a wealth of research from family, twin, and adoption studies. These studies have consistently demonstrated that many psychiatric conditions, including but not limited to obsessive-compulsive disorder, panic disorder, major depressive disorder, bipolar disorder, schizophrenia, and Alzheimer's disease, exhibit a substantial genetic component [10].

The identification of specific genetic variations associated with psychiatric disorders is an ongoing area of research. While significant progress has been made in understanding the genetic underpinnings of these conditions, the field has faced challenges in pinpointing major susceptibility genes. Most identified risk genes are involved in the regulation of biogenic amines, which are critical for mood regulation and reward systems [11]. The polygenic nature of psychiatric disorders indicates that multiple genetic loci contribute to the risk of developing these conditions, rather than a single deterministic genetic cause [12].

Recent advancements in genomic technologies, including genome-wide association studies (GWAS), have facilitated the identification of numerous common genetic variants linked to psychiatric disorders. However, the majority of these variants are non-coding and primarily enrich regulatory regions of the genome, underscoring the complexity of genetic contributions to psychiatric conditions [13].

Moreover, the interaction between genetic predispositions and environmental factors is crucial in understanding the development of psychiatric disorders. Environmental stressors, for instance, can induce stable changes in gene expression and neural circuit function, leading to behavioral alterations. This interplay suggests that while genetic factors are foundational, they are not the sole determinants of psychiatric health [6].

The heritability estimates for psychiatric disorders range significantly, with estimates between 40% to 80% for various conditions, highlighting the importance of genetic contributions [14]. Despite the substantial genetic influence, the field grapples with the "missing heritability" problem, which refers to the difficulty in accounting for the heritable component of psychiatric disorders through identified genetic variants alone [1].

Furthermore, the understanding of genetic contributions to psychiatric disorders is enhanced by the study of epigenetic mechanisms. Epigenetic modifications, such as DNA methylation, have been implicated in the regulation of gene expression related to psychiatric disorders, suggesting that environmental factors can lead to lasting changes in gene activity without altering the underlying DNA sequence [8].

In conclusion, genetics plays a pivotal role in psychiatric disorders, contributing to their etiology through complex interactions with environmental factors. The ongoing exploration of genetic variants, coupled with an understanding of epigenetic influences, continues to illuminate the intricate biological architectures underlying psychiatric conditions, ultimately aiming to improve diagnostic and therapeutic approaches in the field.

2.2 Heritability and Family Studies ​

Genetic factors play a significant role in the etiology and pathogenesis of various psychiatric disorders, as evidenced by numerous family, twin, and adoption studies. These studies have consistently demonstrated a hereditary component in disorders such as schizophrenia, major depressive disorder, bipolar disorder, obsessive-compulsive disorder, panic disorder, and Alzheimer's disease [5][10][15].

The heritability of psychiatric disorders indicates that genetic vulnerability contributes substantially to the risk of developing these conditions. For instance, research has shown that the familial aggregation of psychiatric disorders points to a strong genetic influence, with heritability estimates suggesting that many psychiatric conditions are moderately to highly heritable [2][16]. The genetic architecture of these disorders is complex and often polygenic, involving multiple genetic variants that may interact with environmental factors [3][17].

Quantitative genetic studies have identified several challenges in the field of psychiatric genetics, particularly in understanding the specific genetic variants that contribute to these disorders. Although substantial progress has been made in identifying risk loci through genome-wide association studies (GWAS), the "missing heritability" problem remains a significant issue. This term refers to the gap between the estimated heritability of psychiatric disorders and the proportion of variance in these disorders that can be explained by identified genetic variants [1][18].

Furthermore, the complexity of psychiatric disorders often complicates the identification of specific genetic markers. Psychiatric conditions exhibit etiological heterogeneity, incomplete penetrance, and variable expressivity, making it challenging to pinpoint exact genetic contributions [15]. Recent findings suggest that environmental stressors and gene-environment interactions may also play critical roles in the development of these disorders, indicating that a comprehensive understanding of psychiatric disorders must consider both genetic and environmental factors [2][16].

In conclusion, genetics provides a crucial framework for understanding psychiatric disorders, highlighting the importance of heritable factors in their development. The ongoing research in this field aims to bridge the gap between genetic findings and clinical applications, with the hope of enhancing diagnostic, preventive, and therapeutic strategies in psychiatry [3][5].

3 Major Psychiatric Disorders and Genetic Links ​

3.1 Schizophrenia ​

Genetics plays a significant role in the etiology of psychiatric disorders, particularly in schizophrenia, which is characterized by a complex interplay of genetic and environmental factors. Schizophrenia has a high heritability estimate, with genetic factors accounting for up to 80% of the risk for developing the disorder [19]. This high heritability underscores the importance of genetic contributions in understanding the pathophysiology of schizophrenia.

Recent advancements in genomic research have revealed that schizophrenia is a highly polygenic disorder, meaning that it is influenced by the combined effects of numerous genetic variants. Both common and rare genetic variants have been implicated in the disorder, with genome-wide association studies identifying multiple loci associated with schizophrenia [19][20]. Notably, rare copy number variations have also been linked to schizophrenia, providing insights into the genetic architecture of the disorder [19].

The genetic basis of schizophrenia is further complicated by the discovery of de novo mutations, which are new mutations that occur in individuals with no family history of the disorder [21]. This suggests that genetic risk for schizophrenia can arise not only from inherited genetic variants but also from spontaneous mutations during development. The identification of these mutations has led to a new understanding of the genetic mechanisms underlying schizophrenia and highlights the need for further research into their functional implications [21].

Moreover, the relationship between schizophrenia and other psychiatric disorders has been explored, revealing shared genetic etiology. For instance, genetic correlations have been identified between schizophrenia and bipolar disorder, as well as between schizophrenia and major depressive disorder [7]. This genetic overlap suggests that similar biological pathways may contribute to the pathogenesis of these disorders, potentially informing treatment strategies and diagnostic criteria.

In addition to genetic factors, the role of epigenetics has gained attention in the study of schizophrenia. Epigenetic modifications, such as DNA methylation and histone modifications, can lead to changes in gene expression without altering the underlying DNA sequence. These modifications may be influenced by environmental factors, further complicating the genetic landscape of schizophrenia [22][23]. Understanding how epigenetic mechanisms interact with genetic predispositions could provide new avenues for therapeutic interventions.

Despite the significant advances in understanding the genetic underpinnings of schizophrenia, the translation of these findings into clinical practice remains limited. Current strategies in clinical management of schizophrenia, such as pharmacogenetics and genetic counseling, are still in their infancy [24]. There is a pressing need for the integration of genetic insights into routine clinical practice to enhance patient care and tailor treatment approaches based on individual genetic profiles.

In summary, genetics plays a crucial role in the etiology of schizophrenia, with a complex interplay of multiple genetic variants, epigenetic modifications, and shared genetic risks with other psychiatric disorders. Continued research in this area is essential for unraveling the biological mechanisms of schizophrenia and improving clinical outcomes for affected individuals.

3.2 Bipolar Disorder ​

Genetics plays a significant role in the etiology of psychiatric disorders, particularly in bipolar disorder. Bipolar disorder is characterized by its complex nature, involving both manic and depressive episodes, and is known to aggregate within families, indicating a genetic component. Despite the high heritability estimates of 60-80% for bipolar disorder, the specific genetic determinants remain largely unidentified. Recent analyses have revealed a substantial number of genetic loci associated with the disorder, highlighting the complexity of its genetic architecture.

A comprehensive study involving a multi-ancestry meta-analysis of 158,036 cases of bipolar disorder and 2.8 million controls identified 298 genome-wide significant loci, which is a fourfold increase over previous findings. This analysis demonstrated that genetic associations can vary depending on the ancestry of the participants, with some ancestry-specific associations noted, particularly in East Asian cohorts. The integration of fine-mapping and variant-to-gene mapping approaches led to the identification of 36 credible genes implicated in the etiology of bipolar disorder, emphasizing the importance of both common and rare genetic variants in the disorder's pathophysiology[25].

Furthermore, genetic studies have suggested that the genetic architecture of bipolar disorder may differ based on the source of patient ascertainment and the subtype of the disorder (type I or type II). This highlights the need for a nuanced understanding of the genetic influences on bipolar disorder, as different genetic and environmental factors may interact to contribute to the manifestation of the disorder. The involvement of specific cell types, such as GABAergic interneurons and medium spiny neurons, has also been implicated in the pathophysiology of bipolar disorder, indicating a biological basis for the disorder that extends beyond mere genetic predisposition[25].

In summary, while genetic factors are undeniably important in the development of bipolar disorder, the interplay between these genetic influences and environmental factors, as well as the complex genetic architecture of the disorder, underscores the need for continued research. Understanding these dynamics may lead to improved therapeutic strategies and better patient outcomes in the management of bipolar disorder and other psychiatric conditions.

3.3 Major Depressive Disorder ​

Genetics plays a significant role in the etiology of major depressive disorder (MDD), a common psychiatric illness with a heritability estimate ranging from 30% to 50% [26]. Numerous studies have highlighted the complex interplay between genetic factors and environmental influences in the development of MDD. Family, twin, and adoption studies have consistently demonstrated a genetic component to the disorder, suggesting that individuals with a family history of depression are at an increased risk [10].

Despite extensive research, identifying specific genetic variations that substantially increase the risk of MDD has proven challenging. Most genetic variants associated with MDD appear to have only modest effects on disease risk, indicating that multiple genetic factors, in conjunction with environmental triggers, are likely necessary for the disorder's development [27]. Recent genome-wide association studies (GWAS) have identified over 100 genetic risk loci associated with MDD, confirming its highly polygenic nature [26]. These findings suggest that MDD is influenced by a complex network of genetic interactions rather than a single causative gene.

Furthermore, the genetic architecture of MDD has shown substantial overlap with other psychiatric disorders. Studies have indicated significant genetic correlations between MDD and conditions such as schizophrenia and bipolar disorder [7]. This shared genetic risk underscores the need for a more integrated understanding of psychiatric disorders, as they may share common biological pathways and etiological factors [20].

The interaction between genetic predisposition and environmental factors is critical in understanding MDD. Stressful life events, childhood maltreatment, and other environmental stressors can exacerbate genetic vulnerabilities, leading to the onset of depressive symptoms [28]. Additionally, epigenetic mechanisms, which involve changes in gene expression without altering the underlying DNA sequence, have been implicated in the pathophysiology of MDD. These modifications can be influenced by environmental factors and may contribute to the maladaptive neuronal plasticity observed in individuals with depression [29].

Overall, while genetic factors significantly contribute to the risk of developing MDD, the disorder's complexity necessitates further research to elucidate the specific mechanisms through which genetic and environmental factors interact. Large-scale studies and advances in genomic technologies hold promise for improving our understanding of the genetic underpinnings of MDD and may ultimately inform more effective treatment strategies [22].

3.4 Autism Spectrum Disorders ​

Genetics plays a significant role in the etiology of psychiatric disorders, including Autism Spectrum Disorders (ASD). The heritability of psychiatric conditions has been extensively documented through family, twin, and adoption studies, indicating a strong genetic component in disorders such as schizophrenia, major depression, and bipolar disorder. In the context of ASD, genetic factors are crucial in understanding its complex etiology.

Recent findings from large-scale genome-wide association studies (GWAS) have identified numerous genetic variants associated with ASD. For instance, Liu et al. (2020) curated and compared genes identified from GWAS for various psychiatric traits, including ASD, and highlighted significant genetic overlaps across these traits. A total of 243 cross-trait genes were identified, with chromosome regions such as 5q14.3, 11q23.2, and 7p22.3 exhibiting the highest pleiotropic effects across different psychiatric conditions, including ASD [30].

Moreover, the genetic architecture of psychiatric disorders, including ASD, has been shown to share common pathways. For example, the dopaminergic and serotonergic systems are implicated in multiple psychiatric conditions, and their genetic contributions have been systematically explored. A study by Cabana-Domínguez et al. (2022) identified 67 genes associated with various psychiatric disorders, with significant associations for ASD with the dopaminergic gene set [31].

The role of polygenic risk scores derived from extensive GWAS also underscores the genetic susceptibility to ASD. Shi et al. (2025) demonstrated pervasive associations between genetic risk for ASD and quality of life outcomes, indicating that genetic factors influence not only the manifestation of ASD but also the broader life experiences of affected individuals [3].

Furthermore, the genetic relationship between ASD and other psychiatric disorders has been explored, revealing significant genetic correlations. For instance, a study by Lee et al. (2013) reported that common genetic variants contribute to the heritability of ASD, with evidence suggesting that the genetic risk for ASD overlaps with that of other psychiatric conditions, such as attention-deficit/hyperactivity disorder (ADHD) and major depressive disorder [7].

In conclusion, genetics plays a critical role in the understanding of Autism Spectrum Disorders, with significant evidence supporting the heritability and genetic overlap with other psychiatric disorders. The identification of specific genetic variants and the exploration of common genetic pathways offer valuable insights into the etiology of ASD and highlight the importance of genetics in the broader context of psychiatric disorders.

4 Advances in Genetic Research Methodologies ​

4.1 Genome-Wide Association Studies (GWAS) ​

Genetics plays a significant role in the understanding and etiology of psychiatric disorders, particularly through the application of genome-wide association studies (GWAS). These studies have revolutionized psychiatric genetics by identifying numerous genetic variants associated with mental health conditions. The findings from GWAS have highlighted the heritable nature of psychiatric disorders, demonstrating that all psychiatric phenotypes are influenced by a complex interplay of genetic factors that are often polygenic and involve many pleiotropic variants with incomplete penetrance [32].

The architecture of psychiatric disorders is characterized by the presence of common genetic variants that are associated with multiple disorders. For instance, GWAS have successfully linked hundreds of specific genetic loci to various psychiatric conditions, revealing that many loci robustly associated with multiple forms of psychopathology harbor genes involved in synaptic structure and function [33]. This shared genetic etiology suggests that underlying biological mechanisms may contribute to a range of psychiatric disorders, thereby informing the development of novel therapeutics and stratification of at-risk patients [32].

Moreover, GWAS findings have underscored the importance of early neurodevelopment and neuronal biology in the etiology of psychiatric disorders [32]. The results emphasize that while individual genetic loci may not powerfully determine disease at the population level, they can represent potent treatment targets that may lead to population-wide therapeutic approaches [33]. The genetic architecture of psychiatric disorders is further complicated by the influence of environmental factors and the often-comorbid nature of these conditions [34].

The insights gained from GWAS also facilitate the identification of high-risk individuals and the development of personalized treatment strategies. The polygenic nature of psychiatric disorders implies that many common genetic variants contribute to the risk, necessitating large sample sizes for sufficient statistical power to detect associations [35]. As a result, the Psychiatric Genomics Consortium aims for extensive meta-analyses to uncover additional genetic risk factors across various psychiatric disorders [36].

In conclusion, GWAS have established a clear link between genetics and psychiatric disorders, revealing a complex genetic landscape that underpins these conditions. This knowledge is critical for advancing our understanding of psychiatric genetics and holds promise for improving clinical interventions and therapeutic strategies. The ongoing challenges in translating GWAS findings into practical applications for psychiatric treatment underscore the need for continued research in this evolving field [37].

4.2 Next-Generation Sequencing (NGS) ​

Genetics plays a crucial role in understanding psychiatric disorders, significantly influencing their etiology and the development of personalized treatment strategies. Advances in genetic research methodologies, particularly the emergence of next-generation sequencing (NGS), have revolutionized the field by providing deeper insights into the genetic underpinnings of these complex conditions.

The last decade has seen substantial progress in psychiatric genetics, with evidence indicating that psychiatric disorders are heritable and influenced by thousands of genetic variants acting in concert. Many of these variants are common and present varying degrees of risk across the population, suggesting that every individual possesses a genetic predisposition to psychiatric disorders, ranging from low to high risk [38]. This understanding paves the way for precision psychiatry, where individual genetic profiles can inform risk assessment and clinical decision-making [38].

NGS technologies have become essential in the clinical setting, particularly for diagnosing early-onset and severe neuropsychiatric conditions. They facilitate definitive gene discovery, which is crucial for understanding the biological mechanisms underlying these disorders [39]. The ability to analyze the whole human genome has accelerated the identification of genetic factors associated with psychiatric disorders, including the discovery of de novo mutations that contribute to the pathophysiology of conditions such as schizophrenia and autism [40].

Furthermore, NGS has enhanced our understanding of the genetic architecture of psychiatric disorders, highlighting the importance of copy number variants and single-nucleotide polymorphisms (SNPs) that are enriched in regulatory regions of the genome [41]. These genetic variants can influence gene expression and are implicated in various neurodevelopmental and psychiatric diseases, thus providing a framework for developing targeted therapies [13].

Despite these advances, translating genetic findings into clinical practice remains challenging. Current polygenic risk score tools, which predict individual susceptibility to psychiatric illnesses, have not yet provided clinically actionable insights [38]. However, the precision of these tools is expected to improve, underscoring the necessity for clinician and patient education regarding their potential applications [38].

In summary, the integration of genetic research methodologies, particularly NGS, has opened new avenues for understanding psychiatric disorders. It not only aids in identifying genetic risk factors but also holds promise for improving diagnostic accuracy and tailoring treatment strategies, thereby advancing the field of psychiatry toward a more personalized approach to mental health care.

4.3 Epigenetics and Gene Expression ​

Genetics plays a significant role in the etiology of psychiatric disorders, which are recognized as complex, multifactorial illnesses. The interplay between genetic and environmental factors is critical in understanding the development of these disorders. Family, adoption, and twin studies have demonstrated a clear genetic component in several adult psychiatric conditions, including schizophrenia, major depression, and bipolar disorder. However, the genetic basis of these disorders is not straightforward; it involves a multitude of genes, each contributing to the susceptibility of these conditions through intricate interactions with environmental factors [5].

Recent advances in genetic research methodologies have emphasized the importance of epigenetics in psychiatric disorders. Epigenetics refers to heritable changes in gene expression that do not involve alterations to the underlying DNA sequence. These changes can be induced by environmental influences, thereby acting as a bridge between genetic predispositions and environmental exposures [42]. Epigenetic modifications, such as DNA methylation and histone modifications, play a crucial role in regulating gene expression and can lead to stable changes in neural circuit function and behavior, which are pivotal in the pathophysiology of psychiatric disorders [8].

The role of epigenetics is particularly evident in the context of stress and early life experiences, which can induce long-lasting changes in gene expression patterns. These epigenetic alterations may contribute to the onset and progression of disorders like depression and anxiety [43]. For instance, environmental factors such as poor socio-economic status, obstetric complications, and early life stressors have been shown to influence gene expression through epigenetic mechanisms, thus increasing the risk of developing psychiatric conditions [44].

Moreover, the epigenetic landscape of genes associated with psychiatric disorders, such as BDNF, COMT, and FKBP5, has been studied extensively. These genes are implicated in various mental health conditions, and their epigenetic regulation could serve as potential biomarkers for diagnostics and therapeutic targets [9]. The complexity of psychiatric disorders is further highlighted by the observation that identical twins often exhibit discordance in developing these conditions, suggesting that non-genetic factors, mediated through epigenetic changes, play a significant role [8].

In conclusion, the role of genetics in psychiatric disorders is multifaceted, with epigenetics emerging as a crucial component that bridges genetic predispositions and environmental influences. Understanding these mechanisms not only enhances the knowledge of psychiatric disorder etiology but also opens new avenues for targeted therapeutic interventions aimed at reversing detrimental epigenetic changes that may occur throughout an individual's life [22][44].

5 Gene-Environment Interactions ​

5.1 The Role of Environmental Factors ​

Genetic factors play a significant role in the etiology of psychiatric disorders, as evidenced by family, twin, and adoption studies. These studies have established a clear genetic component in various adult psychiatric disorders, including schizophrenia, major depression, bipolar disorder, and anxiety disorders [5]. The complexities of psychiatric disorders arise from the interplay between genetic predispositions and environmental influences, which together contribute to the manifestation of these conditions.

The concept of gene-environment interactions (GxE) highlights how genetic susceptibility can influence an individual's response to environmental factors. This interaction is critical in understanding the development of psychiatric disorders. For instance, certain genetic profiles may predispose individuals to react more sensitively to environmental stressors, leading to an increased risk of developing mental health issues [45]. This perspective is supported by research indicating that environmental factors, such as socio-economic status, early life stressors, and exposure to adverse experiences, can induce epigenetic changes that alter gene expression and contribute to psychiatric pathogenesis [44].

Environmental factors such as prenatal stress, childhood adversity, and substance abuse have been shown to interact with genetic vulnerabilities, resulting in stable changes in neural circuits and behavior [6]. Moreover, exposure to specific environmental stressors can trigger epigenetic modifications that influence the risk of developing psychiatric disorders [46]. These findings underscore the importance of considering both genetic and environmental components when examining the risk factors for psychiatric illnesses.

In addition, the search for susceptibility genes has encountered challenges, as many candidate gene studies have not consistently replicated findings across populations [47]. Genome-wide association studies (GWAS) are beginning to identify genetic variants associated with psychiatric disorders, but the proportion of phenotypic variance explained remains low, suggesting that environmental interactions may be crucial in elucidating the complex etiology of these conditions [18].

Ultimately, the interplay between genetic predispositions and environmental factors necessitates a comprehensive approach to understanding psychiatric disorders. It emphasizes the need for continued research into how these factors interact to influence mental health outcomes, as well as the potential for personalized therapeutic strategies that consider an individual's unique genetic and environmental context [48].

5.2 Epigenetic Modifications ​

The role of genetics in psychiatric disorders is complex and multifactorial, significantly influenced by gene-environment interactions and epigenetic modifications. Genetic factors are acknowledged to play a critical role in the etiology of various psychiatric conditions; however, the presence of high discordance rates among identical twins for disorders such as depression and schizophrenia indicates that environmental influences are also crucial. These environmental factors can lead to stable changes in gene expression and neural circuit function, ultimately affecting behavior and increasing the risk of psychiatric diseases (Nestler et al., 2016; Klengel and Binder, 2015).

Epigenetic modifications, including DNA methylation, histone modifications, and non-coding RNA regulation, serve as mechanisms through which environmental factors can influence gene expression. These modifications can lead to lasting and stable changes in gene activity without altering the underlying DNA sequence, thereby acting as a bridge between genetic predispositions and environmental influences (Montel Hayes et al., 2025; Panariello et al., 2022). For instance, exposure to adverse environmental conditions such as early life stress, trauma, and socio-economic challenges has been shown to induce epigenetic changes that contribute to the development of psychiatric disorders like major depressive disorder (MDD), bipolar disorder (BP), and post-traumatic stress disorder (PTSD) (Bagot et al., 2014; Klengel and Binder, 2015).

Moreover, specific genes such as BDNF, COMT, FKBP5, NR3C1, SLC6A4, and DRD2 have been implicated in psychiatric disorders, and their expression can be significantly modified by epigenetic processes (Montel Hayes et al., 2025). This suggests that epigenetic marks not only provide insights into the biological mechanisms underlying psychiatric conditions but also hold potential as biomarkers for diagnosis and treatment (Mahgoub and Monteggia, 2013).

The interplay between genetics and epigenetics is further complicated by the evidence of transgenerational epigenetic inheritance, which suggests that epigenetic changes can be passed down through generations, potentially influencing the susceptibility of offspring to psychiatric disorders (Varela et al., 2022). This aspect underscores the importance of considering both genetic and epigenetic factors in understanding the heritability and pathophysiology of mental illnesses.

In summary, while genetic factors are integral to the predisposition to psychiatric disorders, the interactions between these genetic factors and environmental influences, mediated through epigenetic modifications, play a pivotal role in the development and manifestation of these complex conditions. Understanding these interactions may lead to more effective therapeutic strategies and personalized medicine approaches in psychiatry (Kular and Kular, 2018; Schiele et al., 2020).

6 Implications for Treatment and Personalized Medicine ​

6.1 Pharmacogenomics ​

Genetics plays a significant role in psychiatric disorders, influencing both the etiology of these conditions and the efficacy of treatments. The field of pharmacogenomics, which focuses on how genetic variations affect drug response, is increasingly relevant in the context of psychiatric care. This approach aims to personalize treatment based on individual genetic profiles, potentially improving therapeutic outcomes and minimizing adverse effects.

Research indicates that psychiatric disorders often exhibit substantial interindividual variability in treatment responses, which can be attributed to genetic factors. For instance, polymorphisms in genes related to drug metabolism, particularly those encoding cytochrome P450 enzymes, have been shown to impact the pharmacokinetics of various psychotropic medications. Genetic variants, such as those in CYP2D6 and CYP2C19, are particularly significant, as they can influence the metabolism of at least 30 different psychotropic drugs. This variability suggests that individuals may require different dosages or even different medications based on their genetic makeup (Dubovsky 2015) [49].

Moreover, pharmacogenomics has the potential to inform treatment strategies for specific psychiatric conditions. For example, in major depressive disorder (MDD), genetic factors such as variations in the catechol-O-methyltransferase (COMT) gene have been associated with treatment response. The Val108/158Met polymorphism in the COMT gene affects enzyme activity and, consequently, the availability of neurotransmitters like dopamine, which are critical for mood regulation. This genetic influence highlights the need for personalized treatment plans that consider individual genetic profiles to enhance the likelihood of remission (Aygun Kocabas 2012) [50].

Additionally, pharmacogenomic testing has been proposed as a means to optimize drug therapy in various psychiatric disorders. Evidence suggests that genetic factors can predict not only therapeutic efficacy but also the occurrence of adverse drug reactions. For instance, studies have shown that genetic variability can alter the acute effects of psychedelics, such as LSD and psilocybin, indicating that pharmacogenomic testing could improve safety and therapeutic outcomes in psychedelic-assisted therapies (Halman et al. 2025) [51].

Despite the promise of pharmacogenomics, challenges remain in its clinical application. The field is still evolving, and while some genetic markers have been identified, the comprehensive understanding of how these markers influence treatment response is incomplete. Further research is necessary to establish robust guidelines for integrating pharmacogenomic data into clinical practice. Large-scale studies and randomized trials are needed to validate the cost-effectiveness and clinical utility of pharmacogenomic testing in psychiatry (van Westrhenen et al. 2020) [52].

In conclusion, genetics plays a crucial role in the development and treatment of psychiatric disorders. Pharmacogenomics offers a pathway toward personalized medicine in psychiatry, enabling clinicians to tailor treatment plans based on genetic profiles. As research progresses, the integration of pharmacogenomic insights into clinical practice may lead to more effective and safer therapeutic strategies for individuals with psychiatric conditions.

6.2 Future Directions in Treatment Approaches ​

Genetics plays a crucial role in understanding psychiatric disorders, influencing both their etiology and the development of treatment approaches. Recent advancements in psychiatric genetics have provided significant insights into the genetic underpinnings of various psychiatric conditions, revealing that these disorders are not only heritable but also shaped by a complex interplay of multiple genetic variants. Evidence indicates that thousands of genetic variants collectively contribute to the risk of developing psychiatric disorders, with many of these variants being commonly occurring across the population. This suggests that every individual has a genetic predisposition to psychiatric conditions, which varies from low to high risk (Andreassen et al., 2023) [38].

The implications of these genetic findings for treatment and personalized medicine are profound. The emerging field of precision psychiatry aims to utilize individual genetic profiles to tailor risk assessments and inform clinical decision-making. Currently, polygenic risk score tools, which predict genetic susceptibility to mental illness, are not yet clinically actionable, but their precision is expected to improve in the coming years. This progress highlights the need for clinicians and patients to be educated about the potential applications and limitations of genetic testing in psychiatric contexts (Andreassen et al., 2023) [38].

Future directions in treatment approaches are likely to involve the integration of genetic insights into clinical practice. Pharmacogenetics, the study of how genes affect a person's response to drugs, is expected to play a key role in optimizing psychiatric treatment. Genetic variants related to drug metabolism and response have already been identified, suggesting that personalized treatment strategies could be developed based on an individual's genetic makeup (Hoehe & Morris-Rosendahl, 2018) [53]. Additionally, epigenetic mechanisms, which involve modifications that affect gene expression without altering the DNA sequence, are being explored as potential biomarkers for treatment efficacy. Epigenetic changes have been linked to various psychiatric disorders, including schizophrenia and major depressive disorder, indicating that they may serve as predictors of treatment response (Montel Hayes et al., 2025) [9].

However, several challenges remain in translating genetic and epigenetic findings into clinical practice. Issues such as tissue heterogeneity, small sample sizes, and the need for replication of findings hinder the establishment of reliable biomarkers for psychiatric disorders. Future research is essential to identify clinically actionable genetic and epigenetic biomarkers, which could lead to more effective, personalized treatments in psychiatry (Ben David et al., 2023) [54].

In summary, genetics plays a pivotal role in the understanding and treatment of psychiatric disorders, paving the way for personalized medicine approaches. Continued research into the genetic and epigenetic factors influencing psychiatric conditions is vital for developing effective treatment strategies and improving clinical outcomes for individuals affected by these disorders.

7 Conclusion ​

The exploration of genetics in psychiatric disorders has revealed significant insights into the complex interplay between genetic predispositions and environmental factors. Key findings highlight the heritable nature of many psychiatric conditions, with heritability estimates ranging from 30% to 80%, underscoring the importance of genetic contributions. Major psychiatric disorders, including schizophrenia, bipolar disorder, major depressive disorder, and autism spectrum disorders, have been linked to specific genetic variants, showcasing the polygenic architecture of these conditions. Recent advancements in genetic methodologies, particularly genome-wide association studies (GWAS) and next-generation sequencing (NGS), have facilitated the identification of numerous genetic loci associated with psychiatric disorders, providing a clearer understanding of their etiology. Moreover, the role of epigenetics has emerged as a crucial factor, bridging genetic susceptibility and environmental influences. Epigenetic modifications can lead to stable changes in gene expression, influenced by environmental stressors, thereby contributing to the development of psychiatric disorders. Despite these advancements, challenges remain in translating genetic findings into clinical practice, particularly regarding personalized medicine approaches. Future research should focus on integrating genetic and epigenetic insights into clinical settings, enhancing treatment strategies, and improving patient outcomes. As the field evolves, a comprehensive understanding of the genetic underpinnings of psychiatric disorders will be vital for developing targeted interventions and optimizing therapeutic approaches.

References ​

  • [1] Dietrich van Calker;Tsvetan Serchov. The "missing heritability"-Problem in psychiatry: Is the interaction of genetics, epigenetics and transposable elements a potential solution?. Neuroscience and biobehavioral reviews(IF=7.9). 2021. PMID:33757815. DOI: 10.1016/j.neubiorev.2021.03.019.
  • [2] Jordan W Smoller. The Genetics of Stress-Related Disorders: PTSD, Depression, and Anxiety Disorders.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology(IF=7.1). 2016. PMID:26321314. DOI: 10.1038/npp.2015.266.
  • [3] Yingjie Shi;Nina Roth Mota;Barbara Franke;Emma Sprooten. Genetic liability to major psychiatric disorders contributes to multi-faceted quality of life outcomes in children and adults.. Translational psychiatry(IF=6.2). 2025. PMID:40624012. DOI: 10.1038/s41398-025-03443-y.
  • [4] Jay Lombard;P Murali Doraiswamy. What is the role of pharmacogenetics in clinical psychiatry?. Expert opinion on drug metabolism & toxicology(IF=3.4). 2013. PMID:23189950. DOI: 10.1517/17425255.2013.733696.
  • [5] Melissa K Hill;Margaret Sahhar. Genetic counselling for psychiatric disorders.. The Medical journal of Australia(IF=8.5). 2006. PMID:17137456. DOI: 10.5694/j.1326-5377.2006.tb00666.x.
  • [6] Rosemary C Bagot;Benoit Labonté;Catherine J Peña;Eric J Nestler. Epigenetic signaling in psychiatric disorders: stress and depression.. Dialogues in clinical neuroscience(IF=8.9). 2014. PMID:25364280. DOI: .
  • [7] ;S Hong Lee;Stephan Ripke;Benjamin M Neale;Stephen V Faraone;Shaun M Purcell;Roy H Perlis;Bryan J Mowry;Anita Thapar;Michael E Goddard;John S Witte;Devin Absher;Ingrid Agartz;Huda Akil;Farooq Amin;Ole A Andreassen;Adebayo Anjorin;Richard Anney;Verneri Anttila;Dan E Arking;Philip Asherson;Maria H Azevedo;Lena Backlund;Judith A Badner;Anthony J Bailey;Tobias Banaschewski;Jack D Barchas;Michael R Barnes;Thomas B Barrett;Nicholas Bass;Agatino Battaglia;Michael Bauer;Mònica Bayés;Frank Bellivier;Sarah E Bergen;Wade Berrettini;Catalina Betancur;Thomas Bettecken;Joseph Biederman;Elisabeth B Binder;Donald W Black;Douglas H R Blackwood;Cinnamon S Bloss;Michael Boehnke;Dorret I Boomsma;Gerome Breen;René Breuer;Richard Bruggeman;Paul Cormican;Nancy G Buccola;Jan K Buitelaar;William E Bunney;Joseph D Buxbaum;William F Byerley;Enda M Byrne;Sian Caesar;Wiepke Cahn;Rita M Cantor;Miguel Casas;Aravinda Chakravarti;Kimberly Chambert;Khalid Choudhury;Sven Cichon;C Robert Cloninger;David A Collier;Edwin H Cook;Hilary Coon;Bru Cormand;Aiden Corvin;William H Coryell;David W Craig;Ian W Craig;Jennifer Crosbie;Michael L Cuccaro;David Curtis;Darina Czamara;Susmita Datta;Geraldine Dawson;Richard Day;Eco J De Geus;Franziska Degenhardt;Srdjan Djurovic;Gary J Donohoe;Alysa E Doyle;Jubao Duan;Frank Dudbridge;Eftichia Duketis;Richard P Ebstein;Howard J Edenberg;Josephine Elia;Sean Ennis;Bruno Etain;Ayman Fanous;Anne E Farmer;I Nicol Ferrier;Matthew Flickinger;Eric Fombonne;Tatiana Foroud;Josef Frank;Barbara Franke;Christine Fraser;Robert Freedman;Nelson B Freimer;Christine M Freitag;Marion Friedl;Louise Frisén;Louise Gallagher;Pablo V Gejman;Lyudmila Georgieva;Elliot S Gershon;Daniel H Geschwind;Ina Giegling;Michael Gill;Scott D Gordon;Katherine Gordon-Smith;Elaine K Green;Tiffany A Greenwood;Dorothy E Grice;Magdalena Gross;Detelina Grozeva;Weihua Guan;Hugh Gurling;Lieuwe De Haan;Jonathan L Haines;Hakon Hakonarson;Joachim Hallmayer;Steven P Hamilton;Marian L Hamshere;Thomas F Hansen;Annette M Hartmann;Martin Hautzinger;Andrew C Heath;Anjali K Henders;Stefan Herms;Ian B Hickie;Maria Hipolito;Susanne Hoefels;Peter A Holmans;Florian Holsboer;Witte J Hoogendijk;Jouke-Jan Hottenga;Christina M Hultman;Vanessa Hus;Andrés Ingason;Marcus Ising;Stéphane Jamain;Edward G Jones;Ian Jones;Lisa Jones;Jung-Ying Tzeng;Anna K Kähler;René S Kahn;Radhika Kandaswamy;Matthew C Keller;James L Kennedy;Elaine Kenny;Lindsey Kent;Yunjung Kim;George K Kirov;Sabine M Klauck;Lambertus Klei;James A Knowles;Martin A Kohli;Daniel L Koller;Bettina Konte;Ania Korszun;Lydia Krabbendam;Robert Krasucki;Jonna Kuntsi;Phoenix Kwan;Mikael Landén;Niklas Långström;Mark Lathrop;Jacob Lawrence;William B Lawson;Marion Leboyer;David H Ledbetter;Phil H Lee;Todd Lencz;Klaus-Peter Lesch;Douglas F Levinson;Cathryn M Lewis;Jun Li;Paul Lichtenstein;Jeffrey A Lieberman;Dan-Yu Lin;Don H Linszen;Chunyu Liu;Falk W Lohoff;Sandra K Loo;Catherine Lord;Jennifer K Lowe;Susanne Lucae;Donald J MacIntyre;Pamela A F Madden;Elena Maestrini;Patrik K E Magnusson;Pamela B Mahon;Wolfgang Maier;Anil K Malhotra;Shrikant M Mane;Christa L Martin;Nicholas G Martin;Manuel Mattheisen;Keith Matthews;Morten Mattingsdal;Steven A McCarroll;Kevin A McGhee;James J McGough;Patrick J McGrath;Peter McGuffin;Melvin G McInnis;Andrew McIntosh;Rebecca McKinney;Alan W McLean;Francis J McMahon;William M McMahon;Andrew McQuillin;Helena Medeiros;Sarah E Medland;Sandra Meier;Ingrid Melle;Fan Meng;Jobst Meyer;Christel M Middeldorp;Lefkos Middleton;Vihra Milanova;Ana Miranda;Anthony P Monaco;Grant W Montgomery;Jennifer L Moran;Daniel Moreno-De-Luca;Gunnar Morken;Derek W Morris;Eric M Morrow;Valentina Moskvina;Pierandrea Muglia;Thomas W Mühleisen;Walter J Muir;Bertram Müller-Myhsok;Michael Murtha;Richard M Myers;Inez Myin-Germeys;Michael C Neale;Stan F Nelson;Caroline M Nievergelt;Ivan Nikolov;Vishwajit Nimgaonkar;Willem A Nolen;Markus M Nöthen;John I Nurnberger;Evaristus A Nwulia;Dale R Nyholt;Colm O'Dushlaine;Robert D Oades;Ann Olincy;Guiomar Oliveira;Line Olsen;Roel A Ophoff;Urban Osby;Michael J Owen;Aarno Palotie;Jeremy R Parr;Andrew D Paterson;Carlos N Pato;Michele T Pato;Brenda W Penninx;Michele L Pergadia;Margaret A Pericak-Vance;Benjamin S Pickard;Jonathan Pimm;Joseph Piven;Danielle Posthuma;James B Potash;Fritz Poustka;Peter Propping;Vinay Puri;Digby J Quested;Emma M Quinn;Josep Antoni Ramos-Quiroga;Henrik B Rasmussen;Soumya Raychaudhuri;Karola Rehnström;Andreas Reif;Marta Ribasés;John P Rice;Marcella Rietschel;Kathryn Roeder;Herbert Roeyers;Lizzy Rossin;Aribert Rothenberger;Guy Rouleau;Douglas Ruderfer;Dan Rujescu;Alan R Sanders;Stephan J Sanders;Susan L Santangelo;Joseph A Sergeant;Russell Schachar;Martin Schalling;Alan F Schatzberg;William A Scheftner;Gerard D Schellenberg;Stephen W Scherer;Nicholas J Schork;Thomas G Schulze;Johannes Schumacher;Markus Schwarz;Edward Scolnick;Laura J Scott;Jianxin Shi;Paul D Shilling;Stanley I Shyn;Jeremy M Silverman;Susan L Slager;Susan L Smalley;Johannes H Smit;Erin N Smith;Edmund J S Sonuga-Barke;David St Clair;Matthew State;Michael Steffens;Hans-Christoph Steinhausen;John S Strauss;Jana Strohmaier;T Scott Stroup;James S Sutcliffe;Peter Szatmari;Szabocls Szelinger;Srinivasa Thirumalai;Robert C Thompson;Alexandre A Todorov;Federica Tozzi;Jens Treutlein;Manfred Uhr;Edwin J C G van den Oord;Gerard Van Grootheest;Jim Van Os;Astrid M Vicente;Veronica J Vieland;John B Vincent;Peter M Visscher;Christopher A Walsh;Thomas H Wassink;Stanley J Watson;Myrna M Weissman;Thomas Werge;Thomas F Wienker;Ellen M Wijsman;Gonneke Willemsen;Nigel Williams;A Jeremy Willsey;Stephanie H Witt;Wei Xu;Allan H Young;Timothy W Yu;Stanley Zammit;Peter P Zandi;Peng Zhang;Frans G Zitman;Sebastian Zöllner;Bernie Devlin;John R Kelsoe;Pamela Sklar;Mark J Daly;Michael C O'Donovan;Nicholas Craddock;Patrick F Sullivan;Jordan W Smoller;Kenneth S Kendler;Naomi R Wray; . Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs.. Nature genetics(IF=29.0). 2013. PMID:23933821. DOI: 10.1038/ng.2711.
  • [8] Eric J Nestler;Catherine J Peña;Marija Kundakovic;Amanda Mitchell;Schahram Akbarian. Epigenetic Basis of Mental Illness.. The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry(IF=3.9). 2016. PMID:26450593. DOI: 10.1177/1073858415608147.
  • [9] Rachel Montel Hayes;Christopher E Mason;John J Miller. The clinical use of epigenetics in psychiatry: a narrative review of epigenetic mechanisms, key candidate genes, and precision psychiatry.. Frontiers in psychiatry(IF=3.2). 2025. PMID:41234420. DOI: 10.3389/fpsyt.2025.1671122.
  • [10] Regina A Shih;Pamela L Belmonte;Peter P Zandi. A review of the evidence from family, twin and adoption studies for a genetic contribution to adult psychiatric disorders.. International review of psychiatry (Abingdon, England)(IF=3.4). 2004. PMID:16194760. DOI: 10.1080/09540260400014401.
  • [11] Stephan Züchner;Sushma T Roberts;Marcy C Speer;Jean C Beckham. Update on psychiatric genetics.. Genetics in medicine : official journal of the American College of Medical Genetics(IF=6.2). 2007. PMID:17575499. DOI: 10.1097/gim.0b013e318065a9fa.
  • [12] Patrick F Sullivan;Daniel H Geschwind. Defining the Genetic, Genomic, Cellular, and Diagnostic Architectures of Psychiatric Disorders.. Cell(IF=42.5). 2019. PMID:30901538. DOI: 10.1016/j.cell.2019.01.015.
  • [13] Anna Starnawska;Ditte Demontis. Role of DNA Methylation in Mediating Genetic Risk of Psychiatric Disorders.. Frontiers in psychiatry(IF=3.2). 2021. PMID:33868039. DOI: 10.3389/fpsyt.2021.596821.
  • [14] Eco Jc de Geus. From genotype to EEG endophenotype: a route for post-genomic understanding of complex psychiatric disease?. Genome medicine(IF=11.2). 2010. PMID:20828426. DOI: 10.1186/gm184.
  • [15] H Pardes;C A Kaufmann;H A Pincus;A West. Genetics and psychiatry: past discoveries, current dilemmas, and future directions.. The American journal of psychiatry(IF=14.7). 1989. PMID:2648864. DOI: 10.1176/ajp.146.4.435.
  • [16] Barbara Maughan;Edmund J S Sonuga-Barke. Editorial: Translational genetics of child psychopathology: a distant dream?. Journal of child psychology and psychiatry, and allied disciplines(IF=7.0). 2014. PMID:25195502. DOI: 10.1111/jcpp.12323.
  • [17] Bart M L Baselmans;Loïc Yengo;Wouter van Rheenen;Naomi R Wray. Risk in Relatives, Heritability, SNP-Based Heritability, and Genetic Correlations in Psychiatric Disorders: A Review.. Biological psychiatry(IF=9.0). 2021. PMID:32736793. DOI: 10.1016/j.biopsych.2020.05.034.
  • [18] Marcus R Munafò;Stanley Zammit;Jonathan Flint. Practitioner review: A critical perspective on gene-environment interaction models--what impact should they have on clinical perceptions and practice?. Journal of child psychology and psychiatry, and allied disciplines(IF=7.0). 2014. PMID:24828285. DOI: 10.1111/jcpp.12261.
  • [19] Ina Giegling;Ladislav Hosak;Rainald Mössner;Alessandro Serretti;Frank Bellivier;Stephan Claes;David A Collier;Alejo Corrales;Lynn E DeLisi;Carla Gallo;Michael Gill;James L Kennedy;Marion Leboyer;Wolfgang Maier;Miguel Marquez;Isabelle Massat;Ole Mors;Pierandrea Muglia;Markus M Nöthen;Jorge Ospina-Duque;Michael J Owen;Peter Propping;YongYong Shi;David St Clair;Florence Thibaut;Sven Cichon;Julien Mendlewicz;Michael C O'Donovan;Dan Rujescu. Genetics of schizophrenia: A consensus paper of the WFSBP Task Force on Genetics.. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry(IF=3.8). 2017. PMID:28112043. DOI: 10.1080/15622975.2016.1268715.
  • [20] Michael J Owen;Nicholas J Bray;James T R Walters;Michael C O'Donovan. Genomics of schizophrenia, bipolar disorder and major depressive disorder.. Nature reviews. Genetics(IF=52.0). 2025. PMID:40355602. DOI: 10.1038/s41576-025-00843-0.
  • [21] Simon L Girard;Patrick A Dion;Guy A Rouleau. Schizophrenia genetics: putting all the pieces together.. Current neurology and neuroscience reports(IF=5.2). 2012. PMID:22456906. DOI: 10.1007/s11910-012-0266-7.
  • [22] Melissa Mahgoub;Lisa M Monteggia. Epigenetics and psychiatry.. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics(IF=6.9). 2013. PMID:24092614. DOI: 10.1007/s13311-013-0213-6.
  • [23] Schahram Akbarian. Epigenetic mechanisms in schizophrenia.. Dialogues in clinical neuroscience(IF=8.9). 2014. PMID:25364289. DOI: .
  • [24] Aaron D Besterman. A genetics-guided approach to the clinical management of schizophrenia.. Schizophrenia research(IF=3.5). 2024. PMID:37813777. DOI: 10.1016/j.schres.2023.09.042.
  • [25] Kevin S O'Connell;Maria Koromina;Tracey van der Veen;Toni Boltz;Friederike S David;Jessica Mei Kay Yang;Keng-Han Lin;Xin Wang;Jonathan R I Coleman;Brittany L Mitchell;Caroline C McGrouther;Aaditya V Rangan;Penelope A Lind;Elise Koch;Arvid Harder;Nadine Parker;Jaroslav Bendl;Kristina Adorjan;Esben Agerbo;Diego Albani;Silvia Alemany;Ney Alliey-Rodriguez;Thomas D Als;Till F M Andlauer;Anastasia Antoniou;Helga Ask;Nicholas Bass;Michael Bauer;Eva C Beins;Tim B Bigdeli;Carsten Bøcker Pedersen;Marco P Boks;Sigrid Børte;Rosa Bosch;Murielle Brum;Ben M Brumpton;Nathalie Brunkhorst-Kanaan;Monika Budde;Jonas Bybjerg-Grauholm;William Byerley;Judit Cabana-Domínguez;Murray J Cairns;Bernardo Carpiniello;Miquel Casas;Pablo Cervantes;Chris Chatzinakos;Hsi-Chung Chen;Tereza Clarence;Toni-Kim Clarke;Isabelle Claus;Brandon Coombes;Elizabeth C Corfield;Cristiana Cruceanu;Alfredo Cuellar-Barboza;Piotr M Czerski;Konstantinos Dafnas;Anders M Dale;Nina Dalkner;Franziska Degenhardt;J Raymond DePaulo;Srdjan Djurovic;Ole Kristian Drange;Valentina Escott-Price;Ayman H Fanous;Frederike T Fellendorf;I Nicol Ferrier;Liz Forty;Josef Frank;Oleksandr Frei;Nelson B Freimer;John F Fullard;Julie Garnham;Ian R Gizer;Scott D Gordon;Katherine Gordon-Smith;Tiffany A Greenwood;Jakob Grove;José Guzman-Parra;Tae Hyon Ha;Tim Hahn;Magnus Haraldsson;Martin Hautzinger;Alexandra Havdahl;Urs Heilbronner;Dennis Hellgren;Stefan Herms;Ian B Hickie;Per Hoffmann;Peter A Holmans;Ming-Chyi Huang;Masashi Ikeda;Stéphane Jamain;Jessica S Johnson;Lina Jonsson;Janos L Kalman;Yoichiro Kamatani;James L Kennedy;Euitae Kim;Jaeyoung Kim;Sarah Kittel-Schneider;James A Knowles;Manolis Kogevinas;Thorsten M Kranz;Kristi Krebs;Steven A Kushner;Catharina Lavebratt;Jacob Lawrence;Markus Leber;Heon-Jeong Lee;Calwing Liao;Susanne Lucae;Martin Lundberg;Donald J MacIntyre;Wolfgang Maier;Adam X Maihofer;Dolores Malaspina;Mirko Manchia;Eirini Maratou;Lina Martinsson;Manuel Mattheisen;Nathaniel W McGregor;Melvin G McInnis;James D McKay;Helena Medeiros;Andreas Meyer-Lindenberg;Vincent Millischer;Derek W Morris;Paraskevi Moutsatsou;Thomas W Mühleisen;Claire O'Donovan;Catherine M Olsen;Georgia Panagiotaropoulou;Sergi Papiol;Antonio F Pardiñas;Hye Youn Park;Amy Perry;Andrea Pfennig;Claudia Pisanu;James B Potash;Digby Quested;Mark H Rapaport;Eline J Regeer;John P Rice;Margarita Rivera;Eva C Schulte;Fanny Senner;Alexey Shadrin;Paul D Shilling;Engilbert Sigurdsson;Lisa Sindermann;Lea Sirignano;Dan Siskind;Claire Slaney;Laura G Sloofman;Olav B Smeland;Daniel J Smith;Janet L Sobell;Maria Soler Artigas;Dan J Stein;Frederike Stein;Mei-Hsin Su;Heejong Sung;Beata Świątkowska;Chikashi Terao;Markos Tesfaye;Martin Tesli;Thorgeir E Thorgeirsson;Jackson G Thorp;Claudio Toma;Leonardo Tondo;Paul A Tooney;Shih-Jen Tsai;Evangelia Eirini Tsermpini;Marquis P Vawter;Helmut Vedder;Annabel Vreeker;James T R Walters;Bendik S Winsvold;Stephanie H Witt;Hong-Hee Won;Robert Ye;Allan H Young;Peter P Zandi;Lea Zillich; ;Rolf Adolfsson;Martin Alda;Lars Alfredsson;Lena Backlund;Bernhard T Baune;Frank Bellivier;Susanne Bengesser;Wade H Berrettini;Joanna M Biernacka;Michael Boehnke;Anders D Børglum;Gerome Breen;Vaughan J Carr;Stanley Catts;Sven Cichon;Aiden Corvin;Nicholas Craddock;Udo Dannlowski;Dimitris Dikeos;Bruno Etain;Panagiotis Ferentinos;Mark Frye;Janice M Fullerton;Micha Gawlik;Elliot S Gershon;Fernando S Goes;Melissa J Green;Maria Grigoroiu-Serbanescu;Joanna Hauser;Frans A Henskens;Jens Hjerling-Leffler;David M Hougaard;Kristian Hveem;Nakao Iwata;Ian Jones;Lisa A Jones;René S Kahn;John R Kelsoe;Tilo Kircher;George Kirov;Po-Hsiu Kuo;Mikael Landén;Marion Leboyer;Qingqin S Li;Jolanta Lissowska;Christine Lochner;Carmel Loughland;Jurjen J Luykx;Nicholas G Martin;Carol A Mathews;Fermin Mayoral;Susan L McElroy;Andrew M McIntosh;Francis J McMahon;Sarah E Medland;Ingrid Melle;Lili Milani;Philip B Mitchell;Gunnar Morken;Ole Mors;Preben Bo Mortensen;Bertram Müller-Myhsok;Richard M Myers;Woojae Myung;Benjamin M Neale;Caroline M Nievergelt;Merete Nordentoft;Markus M Nöthen;John I Nurnberger;Michael C O'Donovan;Ketil J Oedegaard;Tomas Olsson;Michael J Owen;Sara A Paciga;Christos Pantelis;Carlos N Pato;Michele T Pato;George P Patrinos;Joanna M Pawlak;Josep Antoni Ramos-Quiroga;Andreas Reif;Eva Z Reininghaus;Marta Ribasés;Marcella Rietschel;Stephan Ripke;Guy A Rouleau;Panos Roussos;Takeo Saito;Ulrich Schall;Martin Schalling;Peter R Schofield;Thomas G Schulze;Laura J Scott;Rodney J Scott;Alessandro Serretti;Jordan W Smoller;Alessio Squassina;Eli A Stahl;Hreinn Stefansson;Kari Stefansson;Eystein Stordal;Fabian Streit;Patrick F Sullivan;Gustavo Turecki;Arne E Vaaler;Eduard Vieta;John B Vincent;Irwin D Waldman;Cynthia S Weickert;Thomas W Weickert;Thomas Werge;David C Whiteman;John-Anker Zwart;Howard J Edenberg;Andrew McQuillin;Andreas J Forstner;Niamh Mullins;Arianna Di Florio;Roel A Ophoff;Ole A Andreassen; . Genomics yields biological and phenotypic insights into bipolar disorder.. Nature(IF=48.5). 2025. PMID:39843750. DOI: 10.1038/s41586-024-08468-9.
  • [26] K M Kendall;E Van Assche;T F M Andlauer;K W Choi;J J Luykx;E C Schulte;Y Lu. The genetic basis of major depression.. Psychological medicine(IF=5.5). 2021. PMID:33682643. DOI: 10.1017/S0033291721000441.
  • [27] Falk W Lohoff. Overview of the genetics of major depressive disorder.. Current psychiatry reports(IF=6.7). 2010. PMID:20848240. DOI: 10.1007/s11920-010-0150-6.
  • [28] Charles B Nemeroff. The State of Our Understanding of the Pathophysiology and Optimal Treatment of Depression: Glass Half Full or Half Empty?. The American journal of psychiatry(IF=14.7). 2020. PMID:32741287. DOI: 10.1176/appi.ajp.2020.20060845.
  • [29] Shusaku Uchida;Hirotaka Yamagata;Tomoe Seki;Yoshifumi Watanabe. Epigenetic mechanisms of major depression: Targeting neuronal plasticity.. Psychiatry and clinical neurosciences(IF=6.2). 2018. PMID:29154458. DOI: 10.1111/pcn.12621.
  • [30] Sha Liu;Shuquan Rao;Yong Xu;Jun Li;Hailiang Huang;Xu Zhang;Hui Fu;Qiang Wang;Hongbao Cao;Ancha Baranova;Chunhui Jin;Fuquan Zhang. Identifying common genome-wide risk genes for major psychiatric traits.. Human genetics(IF=3.6). 2020. PMID:31813014. DOI: 10.1007/s00439-019-02096-4.
  • [31] Judit Cabana-Domínguez;Bàrbara Torrico;Andreas Reif;Noèlia Fernàndez-Castillo;Bru Cormand. Comprehensive exploration of the genetic contribution of the dopaminergic and serotonergic pathways to psychiatric disorders.. Translational psychiatry(IF=6.2). 2022. PMID:35013130. DOI: 10.1038/s41398-021-01771-3.
  • [32] Travis T Mallard;Andrew D Grotzinger;Jordan W Smoller. Examining the shared etiology of psychopathology with genome-wide association studies.. Physiological reviews(IF=28.7). 2023. PMID:36634217. DOI: 10.1152/physrev.00016.2022.
  • [33] Laramie Duncan;Karl Deisseroth. Are novel treatments for brain disorders hiding in plain sight?. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology(IF=7.1). 2024. PMID:37422511. DOI: 10.1038/s41386-023-01636-x.
  • [34] Estela M Bruxel;Diego L Rovaris;Sintia I Belangero;Gabriela Chavarría-Soley;Alfredo B Cuellar-Barboza;José J Martínez-Magaña;Sheila T Nagamatsu;Caroline M Nievergelt;Diana L Núñez-Ríos;Vanessa K Ota;Roseann E Peterson;Laura G Sloofman;Amy M Adams;Elinette Albino;Angel T Alvarado;Diego Andrade-Brito;Paola Y Arguello-Pascualli;Cibele E Bandeira;Claiton H D Bau;Cynthia M Bulik;Joseph D Buxbaum;Carolina Cappi;Nadia S Corral-Frias;Alejo Corrales;Fabiana Corsi-Zuelli;James J Crowley;Renata B Cupertino;Bruna S da Silva;Suzannah S De Almeida;Juan F De la Hoz;Diego A Forero;Gabriel R Fries;Joel Gelernter;Yeimy González-Giraldo;Eugenio H Grevet;Dorothy E Grice;Adriana Hernández-Garayua;John M Hettema;Agustín Ibáñez;Iuliana Ionita-Laza;Maria Claudia Lattig;Yago C Lima;Yi-Sian Lin;Sandra López-León;Camila M Loureiro;Verónica Martínez-Cerdeño;Gabriela A Martínez-Levy;Kyle Melin;Daniel Moreno-De-Luca;Carolina Muniz Carvalho;Ana Maria Olivares;Victor F Oliveira;Rafaella Ormond;Abraham A Palmer;Alana C Panzenhagen;Maria Rita Passos-Bueno;Qian Peng;Eduardo Pérez-Palma;Miguel L Prieto;Panos Roussos;Sandra Sanchez-Roige;Hernando Santamaría-García;Flávio M Shansis;Rachel R Sharp;Eric A Storch;Maria Eduarda A Tavares;Grace E Tietz;Bianca A Torres-Hernández;Luciana Tovo-Rodrigues;Pilar Trelles;Eva M Trujillo-ChiVacuan;Maria M Velásquez;Fernando Vera-Urbina;Georgios Voloudakis;Talia Wegman-Ostrosky;Jenny Zhen-Duan;Hang Zhou; ;Marcos L Santoro;Humberto Nicolini;Elizabeth G Atkinson;Paola Giusti-Rodríguez;Janitza L Montalvo-Ortiz. Psychiatric genetics in the diverse landscape of Latin American populations.. Nature genetics(IF=29.0). 2025. PMID:40175716. DOI: 10.1038/s41588-025-02127-z.
  • [35] Johannes Hebebrand;Andre Scherag;Benno G Schimmelmann;Anke Hinney. Child and adolescent psychiatric genetics.. European child & adolescent psychiatry(IF=4.9). 2010. PMID:20140632. DOI: 10.1007/s00787-010-0091-y.
  • [36] Gerome Breen;Qingqin Li;Bryan L Roth;Patricio O'Donnell;Michael Didriksen;Ricardo Dolmetsch;Paul F O'Reilly;Héléna A Gaspar;Husseini Manji;Christopher Huebel;John R Kelsoe;Dheeraj Malhotra;Alessandro Bertolino;Danielle Posthuma;Pamela Sklar;Shitij Kapur;Patrick F Sullivan;David A Collier;Howard J Edenberg. Translating genome-wide association findings into new therapeutics for psychiatry.. Nature neuroscience(IF=20.0). 2016. PMID:27786187. DOI: 10.1038/nn.4411.
  • [37] Julia E H Brown;Jennifer L Young;Nicole Martinez-Martin. Psychiatric genomics, mental health equity, and intersectionality: A framework for research and practice.. Frontiers in psychiatry(IF=3.2). 2022. PMID:36620660. DOI: 10.3389/fpsyt.2022.1061705.
  • [38] Ole A Andreassen;Guy F L Hindley;Oleksandr Frei;Olav B Smeland. New insights from the last decade of research in psychiatric genetics: discoveries, challenges and clinical implications.. World psychiatry : official journal of the World Psychiatric Association (WPA)(IF=65.8). 2023. PMID:36640404. DOI: 10.1002/wps.21034.
  • [39] Anna C Need;David B Goldstein. Neuropsychiatric genomics in precision medicine: diagnostics, gene discovery, and translation.. Dialogues in clinical neuroscience(IF=8.9). 2016. PMID:27757059. DOI: .
  • [40] Julie Gauthier;Guy A Rouleau. De novo mutations in neurological and psychiatric disorders: effects, diagnosis and prevention.. Genome medicine(IF=11.2). 2012. PMID:23009675. DOI: 10.1186/gm372.
  • [41] Daniel Moreno-De-Luca;Joseph F Cubells. Copy number variants: a new molecular frontier in clinical psychiatry.. Current psychiatry reports(IF=6.7). 2011. PMID:21253883. DOI: 10.1007/s11920-011-0183-5.
  • [42] Roger B Varela;José Henrique Cararo;Susannah J Tye;Andre F Carvalho;Samira S Valvassori;Gabriel R Fries;João Quevedo. Contributions of epigenetic inheritance to the predisposition of major psychiatric disorders: Theoretical framework, evidence, and implications.. Neuroscience and biobehavioral reviews(IF=7.9). 2022. PMID:35167845. DOI: 10.1016/j.neubiorev.2022.104579.
  • [43] Mario F Juruena;Romayne Gadelrab;Anthony J Cleare;Allan H Young. Epigenetics: A missing link between early life stress and depression.. Progress in neuro-psychopharmacology & biological psychiatry(IF=3.9). 2021. PMID:33383101. DOI: 10.1016/j.pnpbp.2020.110231.
  • [44] Fabio Panariello;Giuseppe Fanelli;Chiara Fabbri;Anna Rita Atti;Diana De Ronchi;Alessandro Serretti. Epigenetic Basis of Psychiatric Disorders: A Narrative Review.. CNS & neurological disorders drug targets(IF=3.0). 2022. PMID:34433406. DOI: 10.2174/1871527320666210825101915.
  • [45] Ming T Tsuang;Jessica L Bar;William S Stone;Stephen V Faraone. Gene-environment interactions in mental disorders.. World psychiatry : official journal of the World Psychiatric Association (WPA)(IF=65.8). 2004. PMID:16633461. DOI: .
  • [46] Jacob Peedicayil. Genome-Environment Interactions and Psychiatric Disorders.. Biomedicines(IF=3.9). 2023. PMID:37189827. DOI: 10.3390/biomedicines11041209.
  • [47] M J H Kas;C Fernandes;L C Schalkwyk;D A Collier. Genetics of behavioural domains across the neuropsychiatric spectrum; of mice and men.. Molecular psychiatry(IF=10.1). 2007. PMID:17389901. DOI: 10.1038/sj.mp.4001979.
  • [48] Elham Assary;John Paul Vincent;Robert Keers;Michael Pluess. Gene-environment interaction and psychiatric disorders: Review and future directions.. Seminars in cell & developmental biology(IF=6.0). 2018. PMID:29051054. DOI: 10.1016/j.semcdb.2017.10.016.
  • [49] Steven L Dubovsky. The usefulness of genotyping cytochrome P450 enzymes in the treatment of depression.. Expert opinion on drug metabolism & toxicology(IF=3.4). 2015. PMID:25554071. DOI: 10.1517/17425255.2015.998996.
  • [50] Neslihan Aygun Kocabas. Catechol-O-methyltransferase (COMT) pharmacogenetics in the treatment response phenotypes of major depressive disorder (MDD).. CNS & neurological disorders drug targets(IF=3.0). 2012. PMID:22483292. DOI: 10.2174/187152712800672445.
  • [51] Andreas Halman;Rachel Conyers;Claire Moore;Dhrita Khatri;Jerome Sarris;Daniel Perkins. Harnessing Pharmacogenomics in Clinical Research on Psychedelic-Assisted Therapy.. Clinical pharmacology and therapeutics(IF=5.5). 2025. PMID:39345195. DOI: 10.1002/cpt.3459.
  • [52] Roos van Westrhenen;Katherine J Aitchison;Magnus Ingelman-Sundberg;Marin M Jukić. Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going?. Frontiers in psychiatry(IF=3.2). 2020. PMID:32226396. DOI: 10.3389/fpsyt.2020.00094.
  • [53] Margret R Hoehe;Deborah J Morris-Rosendahl. The role of genetics and genomics in clinical psychiatry.. Dialogues in clinical neuroscience(IF=8.9). 2018. PMID:30581286. DOI: .
  • [54] Gil Ben David;Yam Amir;Randa Salalha;Lital Sharvit;Gal Richter-Levin;Gil Atzmon. Can Epigenetics Predict Drug Efficiency in Mental Disorders?. Cells(IF=5.2). 2023. PMID:37190082. DOI: 10.3390/cells12081173.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

Genetics · Psychiatric Disorders · Genomics · Epigenetics · Personalized Medicine

© 2025 MaltSci